社区药剂师对减少阿片类药物和酒精共同使用的影响:一项药物治疗管理干预的随机对照试验

IF 1.5 Q4 PHARMACOLOGY & PHARMACY
Kenneth C. Hohmeier, Grace Broussard, Melissa Tyszko, Kelly Barland, Kristi Carlston, Yingjia Wei, Craig Field, Adam J. Gordon, Alina Cernasev, Gerald Cochran
{"title":"社区药剂师对减少阿片类药物和酒精共同使用的影响:一项药物治疗管理干预的随机对照试验","authors":"Kenneth C. Hohmeier,&nbsp;Grace Broussard,&nbsp;Melissa Tyszko,&nbsp;Kelly Barland,&nbsp;Kristi Carlston,&nbsp;Yingjia Wei,&nbsp;Craig Field,&nbsp;Adam J. Gordon,&nbsp;Alina Cernasev,&nbsp;Gerald Cochran","doi":"10.1002/jac5.70113","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high-risk drinking. We adapted a medication therapy management-based intervention to address co-use and tested its feasibility, acceptability, and preliminary efficacy.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>This pilot study enrolled adult, English-speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol-targeted brief intervention-medication therapy management (ABI-MTM). ABI-MTM included two pharmacist-delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co-use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (&gt; high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI-MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI-MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI-MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>ABI-MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.</p>\n </section>\n </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 10","pages":"991-1002"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Community Pharmacists on Reducing Opioid and Alcohol Co-Use: A Pilot Randomized Control Trial of a Medication Therapy Management Intervention\",\"authors\":\"Kenneth C. Hohmeier,&nbsp;Grace Broussard,&nbsp;Melissa Tyszko,&nbsp;Kelly Barland,&nbsp;Kristi Carlston,&nbsp;Yingjia Wei,&nbsp;Craig Field,&nbsp;Adam J. Gordon,&nbsp;Alina Cernasev,&nbsp;Gerald Cochran\",\"doi\":\"10.1002/jac5.70113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high-risk drinking. We adapted a medication therapy management-based intervention to address co-use and tested its feasibility, acceptability, and preliminary efficacy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>This pilot study enrolled adult, English-speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol-targeted brief intervention-medication therapy management (ABI-MTM). ABI-MTM included two pharmacist-delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co-use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (&gt; high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI-MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI-MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI-MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>ABI-MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.</p>\\n </section>\\n </div>\",\"PeriodicalId\":73966,\"journal\":{\"name\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"volume\":\"8 10\",\"pages\":\"991-1002\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70113\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

阿片类药物和酒精同时使用可导致呼吸抑制、过量和死亡。先前的研究表明,20%-30%在社区药房接受阿片类药物治疗的患者参与高危饮酒。我们采用了一种基于药物治疗管理的干预措施来解决共同使用问题,并测试了其可行性、可接受性和初步疗效。设计本初步研究招募了成人,英语社区药房分配阿片类药物的患者,他们报告目前饮酒。参与者被随机分配到标准药物咨询(SMC)或酒精靶向短期干预药物治疗管理(ABI-MTM)。ABI-MTM包括两次由药剂师主持的会议,重点是回顾药物/相互作用,激励参与者停止共同使用,并提供书面行动计划。我们在基线、2个月和3个月时评估了入组、保留、干预交付、满意度、每饮酒日饮酒量(DDD)和每日吗啡毫克当量(MME)。结果分析采用描述性统计和广义线性混合模型。结果共入组44例(110%),每组22例。年龄(平均值= 55.8)、性别(女性= 65.9%)、种族(白人= 95.5%)、教育程度(高中学历= 95.5%)或健康保险状况(投保= 95.5%)均无显著差异。同意率和保留率超过90%,疗程交付率≥95%,ABI-MTM满意度在79%至89%之间。在3个月时,59.1%的ABI-MTM参与者和45.5%的SMC参与者实现了DDD和/或每日mme减少≥30%。混合模型显示,ABI-MTM接受者实现这一减少的几率高出2.10(95%置信区间= 0.34-12.95)。结论ABI-MTM具有可行性、可接受性和初步疗效。有必要进行全面的试验,以评估更广泛的实施情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Impact of Community Pharmacists on Reducing Opioid and Alcohol Co-Use: A Pilot Randomized Control Trial of a Medication Therapy Management Intervention

Impact of Community Pharmacists on Reducing Opioid and Alcohol Co-Use: A Pilot Randomized Control Trial of a Medication Therapy Management Intervention

Background

Concurrent use of opioids and alcohol can result in respiratory depression, overdose, and death. Prior research has shown that 20%–30% of patients receiving opioid medications in community pharmacies engage in high-risk drinking. We adapted a medication therapy management-based intervention to address co-use and tested its feasibility, acceptability, and preliminary efficacy.

Design

This pilot study enrolled adult, English-speaking community pharmacy patients dispensed opioids who reported current drinking. Participants were randomized to standard medication counseling (SMC) or alcohol-targeted brief intervention-medication therapy management (ABI-MTM). ABI-MTM included two pharmacist-delivered sessions focused on reviewing medications/interactions, motivating participants to discontinue co-use, and providing a written action plan. We assessed enrollment, retention, intervention delivery, satisfaction, drinks per drinking day (DDD), and daily morphine milligram equivalent (MME) at baseline, 2, and 3 months. Outcomes were analyzed using descriptive statistics and generalized linear mixed modeling.

Results

We enrolled 44 patients (110% of target; 22 per group). No significant differences were found in age (mean = 55.8), sex (female = 65.9%), race (White = 95.5%), education (> high school = 95.5%), or health insurance status (insured = 95.5%). Consent and retention rates exceeded 90%, session delivery was ≥ 95%, and ABI-MTM satisfaction ranged from 79% to 89%. At 3 months, 59.1% of ABI-MTM participants versus 45.5% of SMC achieved ≥ 30% reduction in DDD and/or daily MME. Mixed models showed ABI-MTM recipients had 2.10 (95% confidence interval = 0.34–12.95) higher odds of achieving this reduction.

Conclusion

ABI-MTM demonstrated feasibility, acceptability, and preliminary efficacy. A fully powered trial is warranted to evaluate broader implementation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信